arexvy rsv - Search News

News

GSK, RSV and European Medicines Agency

GSK applies to EU regulator for expanded use of RSV vaccine

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults below the age of 50 who are at risk of the disease, the British drugmaker said on Friday.

Pharmabiz · 16h

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha

Yahoo Finance · 1d

GSK (LSE:GSK) Seeks European Expansion Of RSV Vaccine To Adults 18 And Older

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV vaccine, Arexvy, to adults aged 18 and older. This announcement likely supported the company's 14% share price increase last month,

FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

Business Wire1mon

About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

News

GSK, RSV and European Medicines Agency

Trending now